Phase 4
Completed N=50
Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency
Neuromuscular Blockade
Source: ClinicalTrials.gov NCT02860507 ↗
Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcomePrimary: Operating Room (OR) Turnover Time When Using Sugammadex Instead of Combination of Neostigmine and Glycopyrrolate. — 49.7; 49.45 Minutes
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to evaluate the efficacy of Sugammadex in rapidly reversing deep neuromuscular blockaded (induced by rocuronium)
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Operating Room (OR) Turnover Time When Using Sugammadex Instead of Combination of Neostigmine and Glycopyrrolate. |
49.7; 49.45 | — |
| SECONDARY Number of Patients Who Experience Postoperative Nausea and Vomiting, Post-operative Pain, and Post-operative Complications |
8; 10 | — |
Eligibility Criteria
Inclusion Criteria
- Patients scheduled for open ventral hernia repair or open colectomy
- ASA class I-III
- 18 years and older
- Subjects with a body mass index (BMI) of 45 kg/m2 or weight more than 150 kg
Data sourced from ClinicalTrials.gov (NCT02860507). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.